Loading…
Overexpression of aveBIV leading to the improvement of 4′-epidaunorubicin production in Streptomyces coeruleorubidus strain SIPI-A0707
The 4′-epidaunorubicin is the semisynthesis precursor of epirubicin which is a clinically useful antitumor drug thought to have slightly less cardiotoxicity than doxorubin. The 4′-epidaunorubicin was formed by overexpression of heterologous Streptomyces avermitilis aveBIV in Streptomyces coeruleorub...
Saved in:
| Published in: | Applied microbiology and biotechnology 2010-07, Vol.87 (3), p.1057-1064 |
|---|---|
| Main Authors: | , , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c456t-138ea11aa850011f8d106b0acb54340d7ee3f7126cb0ec468c8826117efaf8283 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c456t-138ea11aa850011f8d106b0acb54340d7ee3f7126cb0ec468c8826117efaf8283 |
| container_end_page | 1064 |
| container_issue | 3 |
| container_start_page | 1057 |
| container_title | Applied microbiology and biotechnology |
| container_volume | 87 |
| creator | Shao, Lei Huang, Jia Jing, Lan Chen, Ji-Ye Kan, Shi-Dong Wang, Min Li, Ji-An Chen, Dai-Jie |
| description | The 4′-epidaunorubicin is the semisynthesis precursor of epirubicin which is a clinically useful antitumor drug thought to have slightly less cardiotoxicity than doxorubin. The 4′-epidaunorubicin was formed by overexpression of heterologous Streptomyces avermitilis aveBIV in Streptomyces coeruleorubidus SIPI-A0707 dnmV mutant blocked in the biosynthesis of daunosamine, the deoxysugar component of daunorubicin. But there was a low-yield production of 4′-epidaunorubicin. In our study, product yields were enhanced considerably by increasing aveBIV gene copy number or changing means of aveBIV integration. The 4′-epidaunorubicin titer was improved by around threefold in the recombinant strain DYG1006 with the aveBIV increased threefold copy numbers. The transcript levels of aveBIV gene meet the expectation of fermentation levels of 4′-epidaunorubicin. The method described here provides the means to produce 4′-epidaunorubicin efficiently on an industrial scale. |
| doi_str_mv | 10.1007/s00253-010-2541-3 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_744622889</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2060371561</sourcerecordid><originalsourceid>FETCH-LOGICAL-c456t-138ea11aa850011f8d106b0acb54340d7ee3f7126cb0ec468c8826117efaf8283</originalsourceid><addsrcrecordid>eNp90c1u1DAQB_AIgehSeAAuECFVnAIz_oi9x1IVWKlSkUq5Wo4zWVIl8WInK3rjyPPwSDwJDlmoxIGTZfk347H_WfYU4RUCqNcRgEleAELBpMCC38tWKDgroERxP1sBKlkoudZH2aMYbwCQ6bJ8mB0x4GsQKFbZ98s9Bfq6CxRj64fcN7nd05vNp7wjW7fDNh99Pn6mvO13we-pp2Gckfj57UdBu7a20-DDVLWuHfIk6smNc5-0uxoD7Ubf3zqKufMUpo5-03qKeRyDnc3mw6Y4BQXqcfagsV2kJ4f1OLt-e_7x7H1xcfluc3Z6UTghy7FArskiWqtleg42ukYoK7CukoILqBURbxSy0lVATpTaac1KREWNbTTT_Dh7ufRNw36ZKI6mb6OjrrMD-SkaJUTJmNbrJF_8I2_8FIY0nJHpJyXXUiaEC3LBxxioMbvQ9jbcGgQzh2SWkEwKycwhGZ5qnh0aT1VP9d-KP6kkcHIANjrbNcEOro13jq1lydcqOba4mI6GLYW7Cf93-_OlqLHe2G1Ija-vGCAH1FIBaP4L7-60Dw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>501253855</pqid></control><display><type>article</type><title>Overexpression of aveBIV leading to the improvement of 4′-epidaunorubicin production in Streptomyces coeruleorubidus strain SIPI-A0707</title><source>ABI/INFORM Global</source><source>Springer Link</source><creator>Shao, Lei ; Huang, Jia ; Jing, Lan ; Chen, Ji-Ye ; Kan, Shi-Dong ; Wang, Min ; Li, Ji-An ; Chen, Dai-Jie</creator><creatorcontrib>Shao, Lei ; Huang, Jia ; Jing, Lan ; Chen, Ji-Ye ; Kan, Shi-Dong ; Wang, Min ; Li, Ji-An ; Chen, Dai-Jie</creatorcontrib><description>The 4′-epidaunorubicin is the semisynthesis precursor of epirubicin which is a clinically useful antitumor drug thought to have slightly less cardiotoxicity than doxorubin. The 4′-epidaunorubicin was formed by overexpression of heterologous Streptomyces avermitilis aveBIV in Streptomyces coeruleorubidus SIPI-A0707 dnmV mutant blocked in the biosynthesis of daunosamine, the deoxysugar component of daunorubicin. But there was a low-yield production of 4′-epidaunorubicin. In our study, product yields were enhanced considerably by increasing aveBIV gene copy number or changing means of aveBIV integration. The 4′-epidaunorubicin titer was improved by around threefold in the recombinant strain DYG1006 with the aveBIV increased threefold copy numbers. The transcript levels of aveBIV gene meet the expectation of fermentation levels of 4′-epidaunorubicin. The method described here provides the means to produce 4′-epidaunorubicin efficiently on an industrial scale.</description><identifier>ISSN: 0175-7598</identifier><identifier>EISSN: 1432-0614</identifier><identifier>DOI: 10.1007/s00253-010-2541-3</identifier><identifier>PMID: 20390414</identifier><identifier>CODEN: AMBIDG</identifier><language>eng</language><publisher>Berlin/Heidelberg: Berlin/Heidelberg : Springer-Verlag</publisher><subject>Antibiotics ; Applied Genetics and Molecular Biotechnology ; Bacterial Proteins - genetics ; Bacterial Proteins - metabolism ; Biological and medical sciences ; Biomedical and Life Sciences ; Biosynthesis ; Biotechnology ; Cancer ; Cloning ; Daunorubicin ; Daunorubicin - metabolism ; E coli ; Epidaunorubicin ; Fermentation ; Fundamental and applied biological sciences. Psychology ; Gene expression ; Gene Expression Regulation, Bacterial ; Gene replacement ; Genetic engineering ; Life Sciences ; Medical research ; Microbial Genetics and Genomics ; Microbiology ; Overexpression ; Pharmaceutical industry ; Pharmacology ; Plasmids ; Streptomyces ; Streptomyces - genetics ; Streptomyces - metabolism ; Studies ; Toxicity</subject><ispartof>Applied microbiology and biotechnology, 2010-07, Vol.87 (3), p.1057-1064</ispartof><rights>Springer-Verlag 2010</rights><rights>2015 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c456t-138ea11aa850011f8d106b0acb54340d7ee3f7126cb0ec468c8826117efaf8283</citedby><cites>FETCH-LOGICAL-c456t-138ea11aa850011f8d106b0acb54340d7ee3f7126cb0ec468c8826117efaf8283</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/501253855/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$H</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/501253855?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>314,780,784,11688,27924,27925,36060,36061,44363,74895</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=22956397$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/20390414$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Shao, Lei</creatorcontrib><creatorcontrib>Huang, Jia</creatorcontrib><creatorcontrib>Jing, Lan</creatorcontrib><creatorcontrib>Chen, Ji-Ye</creatorcontrib><creatorcontrib>Kan, Shi-Dong</creatorcontrib><creatorcontrib>Wang, Min</creatorcontrib><creatorcontrib>Li, Ji-An</creatorcontrib><creatorcontrib>Chen, Dai-Jie</creatorcontrib><title>Overexpression of aveBIV leading to the improvement of 4′-epidaunorubicin production in Streptomyces coeruleorubidus strain SIPI-A0707</title><title>Applied microbiology and biotechnology</title><addtitle>Appl Microbiol Biotechnol</addtitle><addtitle>Appl Microbiol Biotechnol</addtitle><description>The 4′-epidaunorubicin is the semisynthesis precursor of epirubicin which is a clinically useful antitumor drug thought to have slightly less cardiotoxicity than doxorubin. The 4′-epidaunorubicin was formed by overexpression of heterologous Streptomyces avermitilis aveBIV in Streptomyces coeruleorubidus SIPI-A0707 dnmV mutant blocked in the biosynthesis of daunosamine, the deoxysugar component of daunorubicin. But there was a low-yield production of 4′-epidaunorubicin. In our study, product yields were enhanced considerably by increasing aveBIV gene copy number or changing means of aveBIV integration. The 4′-epidaunorubicin titer was improved by around threefold in the recombinant strain DYG1006 with the aveBIV increased threefold copy numbers. The transcript levels of aveBIV gene meet the expectation of fermentation levels of 4′-epidaunorubicin. The method described here provides the means to produce 4′-epidaunorubicin efficiently on an industrial scale.</description><subject>Antibiotics</subject><subject>Applied Genetics and Molecular Biotechnology</subject><subject>Bacterial Proteins - genetics</subject><subject>Bacterial Proteins - metabolism</subject><subject>Biological and medical sciences</subject><subject>Biomedical and Life Sciences</subject><subject>Biosynthesis</subject><subject>Biotechnology</subject><subject>Cancer</subject><subject>Cloning</subject><subject>Daunorubicin</subject><subject>Daunorubicin - metabolism</subject><subject>E coli</subject><subject>Epidaunorubicin</subject><subject>Fermentation</subject><subject>Fundamental and applied biological sciences. Psychology</subject><subject>Gene expression</subject><subject>Gene Expression Regulation, Bacterial</subject><subject>Gene replacement</subject><subject>Genetic engineering</subject><subject>Life Sciences</subject><subject>Medical research</subject><subject>Microbial Genetics and Genomics</subject><subject>Microbiology</subject><subject>Overexpression</subject><subject>Pharmaceutical industry</subject><subject>Pharmacology</subject><subject>Plasmids</subject><subject>Streptomyces</subject><subject>Streptomyces - genetics</subject><subject>Streptomyces - metabolism</subject><subject>Studies</subject><subject>Toxicity</subject><issn>0175-7598</issn><issn>1432-0614</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><sourceid>M0C</sourceid><recordid>eNp90c1u1DAQB_AIgehSeAAuECFVnAIz_oi9x1IVWKlSkUq5Wo4zWVIl8WInK3rjyPPwSDwJDlmoxIGTZfk347H_WfYU4RUCqNcRgEleAELBpMCC38tWKDgroERxP1sBKlkoudZH2aMYbwCQ6bJ8mB0x4GsQKFbZ98s9Bfq6CxRj64fcN7nd05vNp7wjW7fDNh99Pn6mvO13we-pp2Gckfj57UdBu7a20-DDVLWuHfIk6smNc5-0uxoD7Ubf3zqKufMUpo5-03qKeRyDnc3mw6Y4BQXqcfagsV2kJ4f1OLt-e_7x7H1xcfluc3Z6UTghy7FArskiWqtleg42ukYoK7CukoILqBURbxSy0lVATpTaac1KREWNbTTT_Dh7ufRNw36ZKI6mb6OjrrMD-SkaJUTJmNbrJF_8I2_8FIY0nJHpJyXXUiaEC3LBxxioMbvQ9jbcGgQzh2SWkEwKycwhGZ5qnh0aT1VP9d-KP6kkcHIANjrbNcEOro13jq1lydcqOba4mI6GLYW7Cf93-_OlqLHe2G1Ija-vGCAH1FIBaP4L7-60Dw</recordid><startdate>20100701</startdate><enddate>20100701</enddate><creator>Shao, Lei</creator><creator>Huang, Jia</creator><creator>Jing, Lan</creator><creator>Chen, Ji-Ye</creator><creator>Kan, Shi-Dong</creator><creator>Wang, Min</creator><creator>Li, Ji-An</creator><creator>Chen, Dai-Jie</creator><general>Berlin/Heidelberg : Springer-Verlag</general><general>Springer-Verlag</general><general>Springer</general><general>Springer Nature B.V</general><scope>FBQ</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QL</scope><scope>7T7</scope><scope>7WY</scope><scope>7WZ</scope><scope>7X7</scope><scope>7XB</scope><scope>87Z</scope><scope>88A</scope><scope>88E</scope><scope>88I</scope><scope>8AO</scope><scope>8FD</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8FL</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BEZIV</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FRNLG</scope><scope>FYUFA</scope><scope>F~G</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K60</scope><scope>K6~</scope><scope>K9.</scope><scope>L.-</scope><scope>LK8</scope><scope>M0C</scope><scope>M0S</scope><scope>M1P</scope><scope>M2P</scope><scope>M7N</scope><scope>M7P</scope><scope>P64</scope><scope>PQBIZ</scope><scope>PQBZA</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7QO</scope></search><sort><creationdate>20100701</creationdate><title>Overexpression of aveBIV leading to the improvement of 4′-epidaunorubicin production in Streptomyces coeruleorubidus strain SIPI-A0707</title><author>Shao, Lei ; Huang, Jia ; Jing, Lan ; Chen, Ji-Ye ; Kan, Shi-Dong ; Wang, Min ; Li, Ji-An ; Chen, Dai-Jie</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c456t-138ea11aa850011f8d106b0acb54340d7ee3f7126cb0ec468c8826117efaf8283</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>Antibiotics</topic><topic>Applied Genetics and Molecular Biotechnology</topic><topic>Bacterial Proteins - genetics</topic><topic>Bacterial Proteins - metabolism</topic><topic>Biological and medical sciences</topic><topic>Biomedical and Life Sciences</topic><topic>Biosynthesis</topic><topic>Biotechnology</topic><topic>Cancer</topic><topic>Cloning</topic><topic>Daunorubicin</topic><topic>Daunorubicin - metabolism</topic><topic>E coli</topic><topic>Epidaunorubicin</topic><topic>Fermentation</topic><topic>Fundamental and applied biological sciences. Psychology</topic><topic>Gene expression</topic><topic>Gene Expression Regulation, Bacterial</topic><topic>Gene replacement</topic><topic>Genetic engineering</topic><topic>Life Sciences</topic><topic>Medical research</topic><topic>Microbial Genetics and Genomics</topic><topic>Microbiology</topic><topic>Overexpression</topic><topic>Pharmaceutical industry</topic><topic>Pharmacology</topic><topic>Plasmids</topic><topic>Streptomyces</topic><topic>Streptomyces - genetics</topic><topic>Streptomyces - metabolism</topic><topic>Studies</topic><topic>Toxicity</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Shao, Lei</creatorcontrib><creatorcontrib>Huang, Jia</creatorcontrib><creatorcontrib>Jing, Lan</creatorcontrib><creatorcontrib>Chen, Ji-Ye</creatorcontrib><creatorcontrib>Kan, Shi-Dong</creatorcontrib><creatorcontrib>Wang, Min</creatorcontrib><creatorcontrib>Li, Ji-An</creatorcontrib><creatorcontrib>Chen, Dai-Jie</creatorcontrib><collection>AGRIS</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>ABI/INFORM Collection</collection><collection>ABI/INFORM Global (PDF only)</collection><collection>ProQuest Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ABI/INFORM Global (Alumni Edition)</collection><collection>Biology Database (Alumni Edition)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ABI/INFORM Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>Business Premium Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Engineering Research Database</collection><collection>Business Premium Collection (Alumni)</collection><collection>Health Research Premium Collection</collection><collection>ABI/INFORM Global (Corporate)</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Business Collection (Alumni Edition)</collection><collection>ProQuest Business Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ABI/INFORM Professional Advanced</collection><collection>ProQuest Biological Science Collection</collection><collection>ABI/INFORM Global</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest Science Journals</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>One Business</collection><collection>ProQuest One Business (Alumni)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>Biotechnology Research Abstracts</collection><jtitle>Applied microbiology and biotechnology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Shao, Lei</au><au>Huang, Jia</au><au>Jing, Lan</au><au>Chen, Ji-Ye</au><au>Kan, Shi-Dong</au><au>Wang, Min</au><au>Li, Ji-An</au><au>Chen, Dai-Jie</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Overexpression of aveBIV leading to the improvement of 4′-epidaunorubicin production in Streptomyces coeruleorubidus strain SIPI-A0707</atitle><jtitle>Applied microbiology and biotechnology</jtitle><stitle>Appl Microbiol Biotechnol</stitle><addtitle>Appl Microbiol Biotechnol</addtitle><date>2010-07-01</date><risdate>2010</risdate><volume>87</volume><issue>3</issue><spage>1057</spage><epage>1064</epage><pages>1057-1064</pages><issn>0175-7598</issn><eissn>1432-0614</eissn><coden>AMBIDG</coden><abstract>The 4′-epidaunorubicin is the semisynthesis precursor of epirubicin which is a clinically useful antitumor drug thought to have slightly less cardiotoxicity than doxorubin. The 4′-epidaunorubicin was formed by overexpression of heterologous Streptomyces avermitilis aveBIV in Streptomyces coeruleorubidus SIPI-A0707 dnmV mutant blocked in the biosynthesis of daunosamine, the deoxysugar component of daunorubicin. But there was a low-yield production of 4′-epidaunorubicin. In our study, product yields were enhanced considerably by increasing aveBIV gene copy number or changing means of aveBIV integration. The 4′-epidaunorubicin titer was improved by around threefold in the recombinant strain DYG1006 with the aveBIV increased threefold copy numbers. The transcript levels of aveBIV gene meet the expectation of fermentation levels of 4′-epidaunorubicin. The method described here provides the means to produce 4′-epidaunorubicin efficiently on an industrial scale.</abstract><cop>Berlin/Heidelberg</cop><pub>Berlin/Heidelberg : Springer-Verlag</pub><pmid>20390414</pmid><doi>10.1007/s00253-010-2541-3</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0175-7598 |
| ispartof | Applied microbiology and biotechnology, 2010-07, Vol.87 (3), p.1057-1064 |
| issn | 0175-7598 1432-0614 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_744622889 |
| source | ABI/INFORM Global; Springer Link |
| subjects | Antibiotics Applied Genetics and Molecular Biotechnology Bacterial Proteins - genetics Bacterial Proteins - metabolism Biological and medical sciences Biomedical and Life Sciences Biosynthesis Biotechnology Cancer Cloning Daunorubicin Daunorubicin - metabolism E coli Epidaunorubicin Fermentation Fundamental and applied biological sciences. Psychology Gene expression Gene Expression Regulation, Bacterial Gene replacement Genetic engineering Life Sciences Medical research Microbial Genetics and Genomics Microbiology Overexpression Pharmaceutical industry Pharmacology Plasmids Streptomyces Streptomyces - genetics Streptomyces - metabolism Studies Toxicity |
| title | Overexpression of aveBIV leading to the improvement of 4′-epidaunorubicin production in Streptomyces coeruleorubidus strain SIPI-A0707 |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T21%3A17%3A41IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Overexpression%20of%20aveBIV%20leading%20to%20the%20improvement%20of%204%E2%80%B2-epidaunorubicin%20production%20in%20Streptomyces%20coeruleorubidus%20strain%20SIPI-A0707&rft.jtitle=Applied%20microbiology%20and%20biotechnology&rft.au=Shao,%20Lei&rft.date=2010-07-01&rft.volume=87&rft.issue=3&rft.spage=1057&rft.epage=1064&rft.pages=1057-1064&rft.issn=0175-7598&rft.eissn=1432-0614&rft.coden=AMBIDG&rft_id=info:doi/10.1007/s00253-010-2541-3&rft_dat=%3Cproquest_cross%3E2060371561%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c456t-138ea11aa850011f8d106b0acb54340d7ee3f7126cb0ec468c8826117efaf8283%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=501253855&rft_id=info:pmid/20390414&rfr_iscdi=true |